Table 3. Management of non metastatic castration- resistant PCa during the COVID-19 era.
| Tumor Stage | Recommendations | Comments |
|---|---|---|
| Nonmetastatic castration- resistant prostate cancer | Consider combination castration therapy with the new hormonal treatments (apalutamide, darolutamide, enzalutamide) in high selected patients. | These drugs have demonstrated benefits in terms of metastatic free survival in patients with PSA-DT < 10 months ( 1 , 15 , 16 ). |
PSA-DT = Prostate Specific Antigen - Doubling Time